NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Rectify Pharma

Rectify Pharma

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://rectifypharma.com/

Last Round

Strategic

Dec 22, 2025

Total Funding Raised

$100M

Company Overview

Rectify Pharma is a biotechnology company developing disease-modifying precision therapies through positive functional modulators that restore ABC transporter function to treat genetic disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

small molecule therapeuticsABC transporterschronic kidney diseaseCKDdrug discoverybiotechpositive functional modulatorPFMtranslational datamedicinal chemistrypreclinical researchbiopharmadrug developmenttherapeutic pipelinetransporter biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Rectify Pharma Comps

Public and private peers based on sector, stage, and business model.

Rectify Pharma comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Rectify Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicDec 22, 2025
Series AOct 14, 2021

Key People

Founding team and executive leadership

Sachiyo Minegishi

Chief Operating Officer

Executive Team

Rectify Pharma Investors

Notable investors and investment history

Rectify Pharma investors
InvestorRounds
Boehringer IngelheimStrategic
Omega FundsSeries A
Dean Capital Investments ManagementSeries A
ForbionSeries A
Atlas VentureSeries A
Longwood FundSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 22, 2025

    Partnered with Boehringer Ingelheim to develop treatments for chronic kidney disease.

  • May 9, 2025

    Presented hepatobiliary program data at the EASL 2025 Congress.

Rectify Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Rectify Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Rectify Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range19
Year Founded2020
Last FundingDec 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.